Ivermectine Glenmark

Ivermectin, the active ingredient in Ivermectine Glenmark, is an anthelmintic presented as an oral formulation for systemic use. It is employed to treat a range of parasitic worm infections and ectoparasitic conditions in adults and children as prescribed by a healthcare professional.

GNH USA supplies Ivermectine Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support export across multiple regions and ensures timely delivery.

Ivermectin is an antiparasitic agent used to treat infections caused by various helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and helps control river blindness. - Strongyloidiasis: eliminates intestinal Strongyloides stercoralis infection. - Scabies: eradicates Sarcoptes scabiei infestation and relieves itching. - Lymphatic filariasis: decreases microfilariae and contributes to disease control programs. - Other helminth infections: treats a variety of soil‑transmitted nematode infections such as ascariasis and hookworm.

Ivermectin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Nausea - Diarrhea

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or other severe skin reactions - Hepatotoxicity with elevated liver enzymes - Neurological events such as seizures or altered consciousness

When prescribing Ivermectine Glenmark, healthcare professionals should consider several precautionary measures to ensure safe use. - Assess for known hypersensitivity: avoid in patients with documented allergy to ivermectin. - Evaluate liver function: monitor hepatic enzymes in patients with pre‑existing liver disease. - Use cautiously in CNS disorders: consider risk of neurotoxicity in patients with compromised blood‑brain barrier. - Review concomitant P‑glycoprotein inhibitors: dose adjustment may be required. - Pregnancy and lactation: weigh potential benefits against unknown risks before use. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivermectin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong P‑glycoprotein inhibitors (e.g., clarithromycin, cyclosporine): may increase ivermectin plasma levels. - Co‑administration with other neurotoxic agents (e.g., benzimidazoles) in patients with CNS disease: heightened risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., azole antifungals, some antiretrovirals): may affect metabolism. - Anticoagulants (e.g., warfarin): monitor INR as ivermectin may potentiate effect. - Antihistamines or corticosteroids used for allergic reactions: monitor for enhanced sedation or skin reactions.